Skip to main content

Table 4 Outcome of patients with severe sepsis and septic shock according to discontinuation or not of ongoing statin therapy in the propensity-matched sample

From: Effects of discontinuing or continuing ongoing statin therapy in severe sepsis and septic shock: a retrospective cohort study

 

Discontinuation group

(n = 19)

Continuation group

(n = 19)

P value

Odds ratio

(95% CI)

Invasive mechanical ventilation, n (%)

13 (68%)

10 (53%)

0.32

0.51 (0.14-1.92)

Duration of invasive mechanical ventilation, days

11 (4-18)

6 (4-31)

0.84

 

Acute Respiratory Distress Syndrome, n (%)

8 (42%)

3 (16%)

0.07

0.26 (0.06-1.19)

Septic shock during ICU stay, n (%)

12 (63%)

13 (68%)

0.72

1.26 (0.33-4.84)

Organ failure free days*

6 (0-12)

9 (6-12)

0.23

 

Organ dysfunction free days*

1 (0-9)

8 (3-11)

0.11

 

Hemodynamic failure free days *

11 (7-14)

12 (7-14)

0.65

 

ICU length of stay, days (ICU survivors, n = 27)

10 (4-17)

6 (5-10)

0.42

 

Hospital length of stay, days (hospital survivors, n = 25)

29 (14-51)

20 (13-37)

0.45

 

ICU deaths, n (%)

5 (26%)

6 (32%)

0.72

1.29 (0.32-5.28)

Hospital deaths, n (%)

7 (37%)

6 (32%)

0.73

0.79 (0.21-3.03)

  1. CI, confidence interval.
  2. * Organ failure free days, organ dysfunction free days, and vasoactive drug free days are calculated at day 14; Organ dysfunction was defined by a sequential organ failure assessment (SOFA) score above one for the appropriate function; Organ failure was defined by a SOFA score above two for the appropriate function.
Back to article page

Critical Care

ISSN: 1364-8535